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Abstract
The Scientific Committee of Molecular Biology Tech-
niques (C-MBT) in Clinical Chemistry of the IFCC has
initiated a joint project in co-operation with the Euro-
pean Commission, Joint Research Centre, Institute of
Reference Materials and Measurements to develop
and produce plasmid-type reference materials (RMs)
for the analysis of the human prothrombin gene
G20210A mutation. Although DNA tests have a high
impact on clinical decision-making and the number of
tests performed in diagnostic laboratories is high,
issues of quality and quality assurance exist, and cur-
rently only a few RMs for clinical genetic testing are
available. A gene fragment chosen was produced that
spans all primer annealing sites published to date.
Both the wild-type and mutant alleles of this gene
fragment were cloned into a pUC18 plasmid and two
plasmid RMs were produced. In addition, a mixture of
both plasmids was produced to mimic the heterozy-
gous genotype. The present study describes the
performance of these reference materials in a com-
mutability study, in which they were tested by nine
different methods in 13 expert laboratories. This
series of plasmid RMs are, to the best of our knowl-
edge, the first plasmid-type clinical genetic RMs intro-
duced worldwide.
Keywords: metrological traceability; molecular diag-
nostic testing; mutation; polymerase chain reaction;
prothrombin; recombinant DNA; reference standards.
Introduction
Recent progress in molecular pathology and biotech-
nology has made DNA-based assays important tools
in patient care. DNA tests allow the detection of
genetic alterations responsible for inheritable disease
conditions, higher risk of developing diseases or
altered drug effects. These tests are increasingly used
for diagnosis, risk stratification and choice of treat-
ment for patients. DNA test results can be predictive
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for future onset of disorders prior to the manifestation
of clinical symptoms, and thus have significant impli-
cations for the individual patient and the sibship.
Often, testing is only carried out once in a lifetime,
and therefore, incorrect genotyping results can have
dramatic consequences for the person tested. Thus,
quality issues and standardisation of DNA tests are
particularly important. Depending on the system
used, relatively high error rates for clinical genetic
testing have been reported (1–4), specifically includ-
ing thrombophilic mutations, such as the prothrom-
bin G20210A mutation (5, 6). To overcome these
issues, the quality of testing has to be assured and
improved.
Certified reference materials (CRMs) are recognised
as an excellent tool for checking analytical accuracy
and are valuable in creating crucial reference points
in the development of comprehensive measurement
systems (7). CRMs are needed to achieve traceability
and comparability of test results and harmonisation
of measurement systems. Suitable reference materi-
als (RMs) are widely used as tools for quality assur-
ance (QA). The in vitro Diagnostic Medical Device
(IVD) Directive of the EC (98/79/EC) (8) has been in
force since December 2003. It requires IVD manufac-
turers to assure the traceability of values assigned to
calibrators and control materials through available
reference measurement procedures and/or available
reference materials of a higher order. The current lack
of CRMs for molecular genetic tests leads to assays
not traceable to an accepted common standard.
Therefore, the Scientific Committee of Molecular Bio-
logy Techniques in Clinical Chemistry (C-MBT) of the
International Federation of Clinical Chemistry and
Laboratory Medicine (IFCC) in co-operation with the
European Commission, Joint Research Centre, Insti-
tute for Reference Materials and Measurements
(IRMM) initiated a joint project to develop and pro-
duce RMs for the analysis of the human prothrombin
gene G20210A mutation. In parallel, batches of the
described RMs were produced as candidate CRMs,
which will be provided as frozen material. These are
currently undergoing an IRMM certification process.
These clinical genetic RMs are among the first RMs
introduced worldwide in this area. Its characteristics
and performance in a collaborative field trial are
described and discussed in the present article.
Background
Selection of prothrombin G20210A mutation as
target
The G20210A mutation in the factor II (prothrombin)
gene was discovered in 1996 by Poort et al. (9). It is
due to a G™A transition at base pair 20210 in the 39
untranslated region of the prothrombin gene. The
heterozygous mutation occurs with a frequency of
approximately 2–5% in the Caucasian population.
Carriers of this mutation have significantly higher
mean plasma prothrombin levels (9). Since the first
publication of the G20210A mutation, it has been
demonstrated in a number of publications that this
genetic variant is a significant and independent risk
factor for venous thromboembolism (VTE) (10). The
clinical significance of this mutation, the indications
for testing and the therapeutic consequences have
been elucidated (11).
Analysis of this single nucleotide polymorphism
(SNP) is one of the most commonly applied genetic
tests in clinical laboratories. Several methods are
used for testing, and commercial kits are increasingly
applied.
Formats of clinical genetic RMs
There are many possible formats of genetic RMs,
including CRMs: cell lines, genomic DNA, recombi-
nant DNA, synthetic DNA or PCR products, all differ-
ing from typical clinical material for investigation. In
the present study, RMs for QA were produced as
freeze-dried plasmid materials. The advantages of
plasmid-type RMs are easy and economical produc-
tion in large quantities, high reproducibility, versatil-
ity, and applicability for qualitative analysis. The main
drawback of these genetic RMs is that they cannot be
used to assess the quality of DNA extraction proce-
dures. In addition, the length of the fragments insert-
ed is limited and commutability will be impaired if
such RMs are applied to methods that use primers
outside of the fragment sequence. RMs must have a
reasonable shelf life to be useful. Therefore, RM sta-
bility is of central importance and has to be guaran-
teed by the producer (12).
Materials and methods
Origin of extracted DNA
The prothrombin gene fragment was selected in the Mole-
cular Biology Division, Department of Clinical Chemistry and
Laboratory Medicine, Medical University Vienna, Vienna,
Austria. To achieve the highest possible level of test com-
patibility and commutability, the fragment chosen spans all
primer annealing sites published to date (GenBank acces-
sion number M17262, nt 26302–26910). Using suitable prim-
ers (Pro-fw, 59-gCACAgACggCTgTTCTCTT-39; and Pro-rev,
59-CCCgAgTgCTCggACTACCA-39, synthesised by VBC Geno-
mics, Vienna, Austria, HPLC-purified) a PCR fragment was
generated from coded samples of individuals previously
tested by other methods and known to carry no mutation or
to carry the G™A mutation at position 20210 (nt 26784 in
the GenBank sequence), respectively.
The individuals had given informed consent to genetic
analysis. The use of coded preserved DNA for means of qual-
ity assurance conforms to the current Austrian and European
regulations.
Cloning of the factor II gene fragment and
processing of the stock plasmids
After initial expansion and characterisation in a pCR2.1 vec-
tor (TA Cloning Kit, Invitrogen GmbH, Lofer, Austria), the
prothrombin gene fragments were amplified with the follow-
ing primers: F2cloning-fw, 59-CgAgCTCggATCCACTAgTAA-
39; and F2cloning-rev, 59-gCCAgTgTgATggATATCTgC-39
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Table 1 Concentrations measured by the PicoGreen meth-
od and copy numbers of the stocks of plasmids pIRMM-0001
(wild-type) and pIRMM-0002 (containing the G20210A
mutation).
Plasmid DNA Copy number,
concentration, cp/mL
mg/mL
pIRMM-0001 306 8.48=1013
pIRMM-0002 298 8.25=1013
Copy numbers were calculated from the concentration val-
ues on the basis of the size of the plasmids (3310 bp for
both).
(Proligo Biochemie GmbH, Hamburg, Germany) and sub-
cloned into the non-patented pUC18 plasmid using the Clon-
tech AdvanTAge PCR Cloning Kit (BD Biosciences Benelux
N.V., Erembodegem, Belgium) according to the instructions
of the manufacturers.
The resulting new plasmids were called pIRMM-0001 and
pIRMM-0002, containing the wild-type or mutant sequence
of the factor II gene fragment, respectively. These plasmids
were introduced into and amplified in the TOP10 competent
E. coli strain provided in the cloning kit.
Amplification and production of stock plasmids
Streaks of bacterial colonies were tested by PCR for the
presence of the inserts. The orientation of the inserts was
assessed by digestion with HindIII. A single clone containing
the wild-type or mutant fragment, respectively, in the same
orientation was selected and used as the source of the plas-
mid stocks for the CRMs.
Plasmid stocks were obtained after amplification overnight
in liquid LB broth medium (LB Ampicillin-100 Broth; Fluka,
Sigma, Bornem, Belgium) containing 100 mg/mL ampicillin
and purification using a Qiagen Plasmid Maxi Kit (Qiagen,
Westburg, Leusden, Netherlands).
DNA quantitation
The stock solution (Tris-HCl) of plasmid DNA was quantified
using the PicoGreen dsDNA quantitation kit (Molecular
Probes, VWR International, Leuven, Belgium) according to
the manufacturer’s instructions. The copy number of the
plasmids in the stock solution was calculated on the basis of
DNA concentration.
Sequencing of the stock plasmids
The factor II gene inserts in the stock plasmids were
sequenced for confirmation using the primers (Pro-fw and
Pro-rev) described above and CEQ Dye Terminator Cycle
Sequencing Kit with the Beckman CEQ2000XL Sequencer
(Beckman Coulter Inc.) according to the manufacturer’s
instructions.
Production of pIRMM-0001, -0002 and mixed RMs
Sterile, self-standing, high-recovery 1.5-mL polypropylene
vials were filled with either 5=104 copies of plasmid pIRMM-
0001, 5=104 copies of pIRMM-0002 or a mixture of 2.5=104
copies of pIRMM-0001 and 2.5=104 copies of pIRMM-0002
in a volume of 100 mL containing 100 mg/mL bovine serum
albumin (BSA) as additive. These samples were freeze-dried
(FD) in a CHRIST LPC-16 EPS 2-65DS freeze-dryer, and the
vials were stored at y208C.
The Quality Management System of the IRMM Reference
Materials Unit is in compliance with the requirements of ISO
Guide 34 and ISO 17025. Characterisation of RMs is per-
formed according to the requirements given by ISO Guide
35.
Commutability study
Commutability as a property of genetic RMs can be
described as showing behaviour similar to usual clinical
samples giving the true result when investigated by different
routine genotyping procedures. To evaluate the commuta-
bility of the RMs, a field study was performed. In the absence
of any reference method for genetic testing, RMs have to
be evaluated by a consensus of recognised reference
laboratories.
A total of 16 leading laboratories in the field of testing for
genetic mutations in coagulation factor genes were invited
to participate in the field study. Of these expert laboratories,
13 responded positively and participated in the study.
Two vials of each genotype and two vials without DNA,
but containing the RM matrix, giving a total of eight vials,
were coded, graded randomly, named as Samples A–H, and
sent on ice to each laboratory for testing.
The testing laboratories were provided with the study pro-
tocol, the terms to be used for reporting, and the result
reporting form, but had no information on the expected
results. In the study protocol, the aim of the study, properties
of samples (content and minimal sample intake, stability and
storage, warning to users), preparation (reconstitution) of
the materials and reporting requirements were described in
detail. The following details were required on the result
reporting form: title and address of the laboratory; number
of genetic tests performed yearly (factor II G20210A and in
general); involvement in proficiency testing programmes for
Factor II G20210A mutation and the relevant organisation;
dates of arrival and testing; storage conditions; and inciden-
tal observations on the samples. The laboratories were
asked to describe the methods used in detail and to report
the genotyping results in a standardised form. Further com-
ments on results were welcomed.
Results
Analysis of the different colonies revealed that all
clones contained the plasmids. DNA concentrations of
the plasmid preparations were evaluated by Pico-
Green quantitation. The results and calculated copy
numbers are listed in Table 1.
Sequencing
Sequence analysis of the selected fragments showed
that the isolated 609-bp sequences were identical to
the GenBank reference sequence (accession number
M17262, nt 26302–26910), except for the G20210A
mutation (corresponding to nt 26784 in the reference
sequence) and an A™G point mutation at position
20054 (nt 26628 in the GenBank reference sequence).
Interestingly, this second mutation was already pres-
ent in the patient sample and was linked to the mu-
tated sequence. The cloned wild-type fragment
corresponded to 100% of the reported prothrombin
sequence. A map of the pUC18 plasmids produced is
shown in Figure 1.
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Figure 1 Map of plasmid pIRMM-0001. pIRMM-0001 and pIRMM-0002 are pUC18 plasmids containing the EcoRI fragment of
the factor II gene insert from plasmid pCR2.1. The factor II mutation G20210A is located at position 491. Plasmid pIRMM-0001
contains G at the position corresponding to the wild-type sequence; pIRMM-0002 reads A at the same locus, representing the
G20210A mutation.
Table 2 Methods used in the testing laboratories for determination.
Laboratory code Method(s) Reference(s) and remark(s) Primers
1 LightCycler, Roche kit Confidential, not communicated
2 LightCycler, Roche kit 32 cycles instead of the original 45
3 PCR-RFLP (HindIII) Poort SR et al. (9), modified using an A-fw, A-rev
elongated mutagenic primer
4 LightCycler, Roche kit; Confidential, not communicated B-fw, B-rev
PCR-RFLP (HindIII) Poort et al. (9)
5 PCR-RFLP (HindIII) Danneberg et al. (13) C-fw, C-rev
6 PCR-RFLP (HindIII) In-house method, not published earlier D-fw, D-rev
7 LightCycler, see reference; Aslanidis et al. (14) E-fw, E-rev;
PCR-RFLP (HindIII) Hybridisation probes: E-det and E-anch B-fw, B-rev
Poort et al. (9)
8 LightCycler, Roche kit Confidential, not communicated
9 Taq-Cycle-Sequencing ABI PRISM 310 Genetic Analyser and F-fw, F-rev
Big Dye Terminator Kit (Applied
Biosystems, Darmstadt, Germany)
10 PCR-RFLP (HindIII) Poort et al. (9) B-fw, B-rev
11 Mutagenically separated PCR Endler et al. (15) G-fw, G-revA
G-revG
12 LightCycler, Roche kit Confidential, not communicated
13 Mutagenically separated PCR In-house method developed with
an industrial partner, confidential
Primer and probe sequences known are described in Figure 2.
Commutability study
For analysis of the samples, nine different methods
were used; two of the laboratories applied two differ-
ent methods, which were reported separately. The
method used most often was real-time PCR using the
LightCycler (LC) system and kit commercially availa-
ble from Roche (Roche Diagnostics Belgium, Vil-
voorde, Belgium). This method is based on the
fluorescence resonance energy transfer (FRET) tech-
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Figure 2 Reference sequence of the prothrombin gene fragment chosen (nt 26302–26910, GenBank accession number
M17262) with the positions of primers and probes used by different testing laboratories. The sequence of the wild-type gene
fragment inserted fully corresponds to the reference sequence represented by bold characters with position numbers at the
beginning of the lines. The G20210A mutation (position nt 26784) is indicated by a capital G. The A™G variation at nt 26628
found in the mutated fragment has not been described previously. The position of this mutation is marked by a capital A. It
is linked to the G20210A mutation in the selected DNA. Primers and probes used by the testing laboratories are positioned
at their annealing sites and marked with the abbreviations used in Table 2. Mismatching nucleotides of PCR primers are
underlined. PCR-RFLP methods published use HindIII digestion for mutation detection following the introduction of a restric-
tion site in the presence of mutation by mutagenic primers. This potential restriction site is highlighted in grey. The prothrom-
bin gene contains another HindIII restriction site close to the G20210A mutation, which can be used as an internal control for
HindIII digestion (13). This site is double-underlined.
nology. One laboratory used the LightCycler with an
in-house FRET method. Six laboratories used PCR
amplification followed by HindIII digestion, and two
laboratories used multiplex PCR with allele-specific
primers.
Every RM was genotyped correctly and no amplifi-
cation or genotype was reported for the blank sam-
ples. However, one laboratory that used the Roche
commercial kit for the LightCycler with a reduced
number of cycles (32 instead of 45 recommended in
the kit) reported a low signal intensity. When the test
was repeated using 45 cycles, the intensity was
appropriate. For the mixed RM, to mimic the hetero-
zygous genotype, it was reported that signal intensi-
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ties for both alleles were similar for the different
methods.
The testing methods are listed in Table 2. The prim-
ers and probes with known sequences used by the
testing laboratories are listed in Figure 2.
Discussion
Suitable CRMs are urgently needed in the field of
human genetic testing (16, 17).
The advantages of plasmid-type RMs include easy
and economical production in large quantities, high
reproducibility, versatility, and applicability for quali-
tative analysis. The major drawback of these genetic
RMs is that they cannot be used to assess the quality
of DNA extraction procedures. In addition, the length
of the fragments inserted is limited. Cloned plasmid-
type RMs contain only one defined specific sequence,
and similar sequences, which might be of importance
when using a certain method, would not be within the
scope of the investigation. This restricted commuta-
bility represents one limit for the wider use of such
RMs.
Assays for defined point mutations, such as the
G20210A mutation in the prothrombin gene, usually
amplify short fragments, and thus the problem can be
tackled by appropriate selection of the fragment
inserted into the plasmid.
Most genetic tests for the detection of mutations or
polymorphisms are qualitative rather than quantita-
tive – their purpose is to determine the presence or
absence of a particular DNA sequence. Accordingly,
the concentration of the target sequence is not a key
issue, but quantification was the basis for checking for
appropriate copy numbers in the RMs. Considering
the uncertainty of this calculation and possible DNA
degradation during the freeze-drying and reconstitu-
tion process, the concentration (5=104 copies/vial)
given is only a nominal value, supplied as additional
material information.
It was demonstrated in the study that the concen-
tration of such plasmid DNA is not critical, as the
detection limit of the testing methods is high and low
concentrations of test material can usually be com-
pensated by an increase in cycle numbers. Even
under assay conditions optimised for high DNA con-
centrations of test material, when the RMs did not
give satisfactory signal intensity, the sample volume
could be increased at the expense of water in the PCR
test to correct for weak signals. Consequently, in
future production of CRMs, the copy numbers could
be increased to allow sample sizes of 1 mL.
From another point of view, such RMs could be a
possible source of contamination in PCR analysis if
not handled appropriately. Obviously, RMs presented
as PCR products or plasmids are good templates for
most of the amplification primers utilised and may
require specific handling procedures. Appropriate
preservation of the RM to keep the copy number of
the target sequence low represents an efficient tool to
reduce contamination risk.
Sequence analysis confirmed that the reference
sequences of the RMs produced are identical to the
GenBank reference sequence, except for the G20210A
mutation and an A™G point mutation at position
20054 in the mutated sequence. This second mutation
was linked to the mutated sequence and was already
present in the patient sample, which means that it
was not introduced during production. To the best of
our knowledge, this sequence change has not been
reported previously and any associations with patho-
logical conditions are unknown. Recently, an A™G
exchange at position 19911 has been identified. This
mutation seems to affect the splicing efficiency of pro-
thrombin (18). The A20054G mutation did not cause
any problems during production of the plasmid-type
RMs or in the field study. However, difficulties may
arise when a primer is used that binds with its 39 end
to this sequence. Therefore, this sequence alteration
is reported in the documentation of the CRMs.
Comparable studies are being performed within the
framework of a shared cost project, which is partly
funded by the European Commission under FP5
‘‘CRMGEN’’, in which IRMM is a partner. This is a fea-
sibility study for the development of different RM pro-
totypes in the field of genetic testing, such as
plasmid-type RMs.
Conclusion
In conclusion, in the present study initiated by the
IFCC C-MBT, it could be shown that plasmid-type RMs
containing defined point mutations can be produced
and successfully used in tests for detection of point
mutations in a typical QA scheme. At present, the cor-
responding CRMs have been produced as frozen
material, which will be delivered under defined con-
ditions at y208C until a successful long-term stability
study has been carried out to determine the success
of freeze-drying techniques. Whether or not the pro-
cedure is also suitable for RMs (including CRMs) con-
taining repetitive sequences of variable length still
needs to be evaluated in depth.
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